ADORA2A and hereditary clear cell renal cell carcinoma: A phase 1 clinical trial demonstrated that a small molecule antagonist of the A2AR can safely block adenosine signaling and promotes tumor regression and improve patient survival in refractory renal cell carcinoma.53